Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Advagene Biopharma Co's Enterprise Value is NT$1,135.45 Mil.
Advagene Biopharma Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was NT$-92.07 Mil. Therefore, Advagene Biopharma Co's EV-to-EBIT ratio for today is -12.33.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Advagene Biopharma Co's Enterprise Value is NT$1,135.45 Mil.
Advagene Biopharma Co's EBITDA for the trailing twelve months (TTM) ended in Jun. 2023 was NT$-80.07 Mil. Therefore, Advagene Biopharma Co's EV-to-EBITDA ratio for today is -14.18.
Advagene Biopharma Co Enterprise Value Historical Data
The historical data trend for Advagene Biopharma Co's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Advagene Biopharma Co's Enterprise Value
For the Biotechnology subindustry, Advagene Biopharma Co's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Advagene Biopharma Co's Enterprise Value Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Advagene Biopharma Co's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Advagene Biopharma Co's Enterprise Value falls into.
Advagene Biopharma Co Enterprise Value Calculation
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Advagene Biopharma Co's Enterprise Value for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Advagene Biopharma Co (ROCO:6709) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Advagene Biopharma Co's current Enterprise Value is NT$1,135.45 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Advagene Biopharma Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was NT$-92.07 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Advagene Biopharma Co's EV-to-EBITDA for today is:
Advagene Biopharma Co's current Enterprise Value is NT$1,135.45 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Advagene Biopharma Co's EBITDA for the trailing twelve months (TTM) ended in Jun. 2023 was NT$-80.07 Mil.
Advagene Biopharma Co's current Enterprise Value is NT$1,135.45 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Advagene Biopharma Co's Revenue for the trailing twelve months (TTM) ended in Jun. 2023 was NT$0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Advagene Biopharma Co Enterprise Value Related Terms
Thank you for viewing the detailed overview of Advagene Biopharma Co's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Advagene Biopharma Co (ROCO:6709) Business Description
Advagene Biopharma Co Ltd is a Taiwan based immune-modulatory platform-based drug developer. The company has completed technology transfer with DCB for detoxified LT Adjuvant Technology Platform. Its product development includes nasal spray influenza vaccine (LT-Flu), allergy vaccines (LT-Allergy), and other vaccines.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ROCO:6709 has been successfully added to your 